Abstract 2405P
Background
At present, the prognostic stratification of urothelial carcinoma(UC) patients heavily relies on tumor staging, which is limited by the quality of the tissue samples assessed. Recently, circulating tumor DNA(ctDNA) has shown potential as a molecular tool for the diagnosis, staging, and prognosis of UC. We aimed to conduct a systematic review and meta-analysis to evaluate the prognostic value of ctDNA in patients with UC.
Methods
The MEDLINE, EMBASE, and the Cochrane Library databases were searched from the inception to March 2023 to identify studies investigating the relationship between detection of ctDNA and clinical outcomes in patients with UC. Hazard ratios (HRs) of disease-free survival (DFS) and overall survival (OS) were extracted and meta-analysis was performed using the R software (version 4.2.1).
Results
Twelve studies with 1844 patients were ultimately included in this meta-analysis. Ten studies assessed the relationship between baseline ctDNA detection and patient outcomes. Patients with an elevated ctDNA level exhibited significantly worse DFS (HR=6.22; 95% CI, 3.78-10.25, p<0.001) and OS (HR=4.09; 95% CI, 3.02-7.96, p<0.001). Similar results were observed in subgroup analyses in patients with muscle-invasive UC and metastatic UC, respectively. Four studies evaluated the prognostic value of ctDNA dynamics during treatment or observation. Patients who exhibited a decrease or clearance in ctDNA levels demonstrated a more favorable DFS (HR=0.31, 95% CI, 0.16–0.59, p=0.0003) and OS (HR=0.24, 95% CI, 0.14–0.43,P<0.001) compared to those who did not.
Conclusions
Our meta-analysis demonstrated a robust correlation between levels of plasma ctDNA at baseline/during treatment and oncologic outcomes in patients with UC. These findings indicate that plasma ctDNA offers substantial clinical utility in the risk stratification and personalized prognosis of patients.
Clinical trial identification
The protocol for this review is registered on PROSPERO (CRD42023414380).
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2380P - Real-world effectiveness of single agent enfortumab vedotin (EV) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC) based on line of therapy and impact of prior platinum (plat) chemotherapy (chemo) and PD-1/PD-L1 inhibitors (PD-1/PD-L1i)
Presenter: Nicolas Sayegh
Session: Poster session 24
2381P - Perceived unmet needs and challenges faced by patients with advanced bladder cancer (aBC) and their caregivers: Results of a social media listening (SML) study conducted in 5 European countries
Presenter: Stephane Schuck
Session: Poster session 24
2382P - EBANO study: Clinical characteristics, treatment patterns and survival results in patients with locally advanced/metastatic urothelial carcinoma (la/mUC) in northern Spain
Presenter: Ricardo Fernandez-Rodriguez
Session: Poster session 24
2383P - Stereotactic body radiotherapy (SBRT) of patients with oligometastatic urothelial cancer (UC): A single institution experience
Presenter: Faith Jawdat
Session: Poster session 24
2384P - Platinum rechallenge in the era of immune checkpoint inhibitor in locally advanced/metastatic urothelial carcinoma: Multicenter retrospective study
Presenter: Eojin Kim
Session: Poster session 24
2385P - Long-term survival upon anti-PD-(L)1 monotherapy in metastatic urothelial cancer (mUC): A multicenter retrospective study
Presenter: Chantal Stockem
Session: Poster session 24
2386P - Factors associated with not receiving systemic treatment (tx) in patients (pts) with metastatic urothelial carcinoma (mUC): Results of a retrospective observational study in Germany
Presenter: Günter Niegisch
Session: Poster session 24
2387P - Avelumab first-line maintenance (1LM) for locally advanced or metastatic urothelial carcinoma (la/mUC): Treatment (tx) patterns and real-world (rw) outcomes in the US
Presenter: Kenneth Carson
Session: Poster session 24
2390P - Correlation between overall survival and bladder-intact event-free survival in cystectomy-ineligible/refusal muscle-invasive bladder cancer patients in Sweden
Presenter: Kelvin Kwok
Session: Poster session 24